Sabestomig  (Synonyms: AZD7789)

Sabestomig (AZD7789) is a monovalent bispecific antibody targeting PD-1 and TIM-3. Sabestomig binds to PD-1 and an epitope in the TIM-3 IgV domain outside the phosphatidylserine-binding cleft, thereby precisely regulating immune responses. Sabestomig promotes IL-2 production, efferocytosis and cross-presentation of tumor antigens, and enhances the release of anti-tumor T cell cytokines, cytotoxicity, and secretion of IFN-γ. Sabestomig inhibits the growth of solid tumors, prolongs the duration of tumor suppression, and significantly enhances anti-tumor responses following anti-PD-1 therapy. Sabestomig has been used in studies related to non-small cell lung cancer and classical Hodgkin lymphoma^[1][2][3].

Human IgG1 kappa

Human IgG1 kappa, Isotype Control

Human

PDCD1 & HAVCR2

Sabestomig enhances efferocytosis and tumor antigen cross-presentation in human monocyte-derived dendritic cells^[1].
Sabestomig increases anti-tumor T-cell responses in co-cultures of PD-1⁺ TIM-3⁺ virally-reactive human T-cells and viral peptide-expressing tumor cell lines, with greater activity than anti-PD-1 or a PS-blocking PD-1/TIM-3 bispecific antibody^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Sabestomig prolongs in vivo tumor growth inhibition in tumors resistant to anti-PD-1 monotherapy^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

5133  [NCBI] & 84868  [NCBI]

Q15116 & Q8TDQ0

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

2648346-74-9

Liquid

Colorless to light yellow

Shipping with dry ice.

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  IgG1-lambda-kappa

• 
  Immobilized PD-1 Protein, Human (HEK293, His, HY-P7396) can bind Sabestomig. The EC₅₀ for this effect is 23.46 ng/mL.
• 
  Immobilized TIM-3/HAVCR2 Protein, Human (HEK293, His HY-P70482) can bind Sabestomig. The EC₅₀ for this effect is 32.83 ng/mL.

• [1]. Clancy-Thompson E, Perry T, Pryts S, et al. 461 Generation of AZD7789, a novel PD-1 and TIM-3 targeting bispecific antibody, which binds to a differentiated epitope of TIM-3[J]. 2022.

  [2]. Wen J, et al. Application and future prospects of bispecific antibodies in the treatment of non-small cell lung cancer. Cancer Biol Med. 2025;22(4):348-375.

  [3]. Besse B, Italiano A, Cousin S, et al. 1313MO Safety and preliminary efficacy of AZD7789, a bispecific antibody targeting PD-1 and TIM-3, in patients (pts) with stage IIIB–IV non-small-cell lung cancer (NSCLC) with previous anti-PD-(L) 1 therapy[J]. Annals of Oncology, 2023, 34: S755.